Bioxtract SA
0.5 FTEThe score of Bioxtract shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +93 % Total assets +39 % Headcount (avg FTE) -78 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Bioxtract's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Jul 2026
- Year ended 31 Dec 2024filed on 30 Jul 2025
- Year ended 31 Dec 2023filed on 29 Aug 2024
- Year ended 31 Dec 2022filed on 25 Aug 2023
- Year ended 31 Dec 2021filed on 26 Aug 2022
Bioxtract's financial analysis
- Solvency96.6%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Bioxtract
Bioxtract's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0480.174.942
- VAT number
- BE0480174942
- Peppol
- Registered · 0208:0480174942 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 08 May 2003
- Registered office
- 5377 Somme-Leuze
- Size
- Micro · 0.5 FTE
- Latest accounts
- 2025 · filed on 31 Jul 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
Bioxtract (SA) has been based in Somme-Leuze since 2003, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net profit of 31,064 € and equity of €1.05m; its revenue is not published. With 0.5 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 96.6%, above the median of its sector (58.2%).
Companies similar to Bioxtract
Companies in the same business, of comparable size and area, outside its group.
- FlyCARE Retail sale of medical and orthopaedic goods Uccle · balance sheet €1.47m
- Arthro ID Research and experimental development on natural sciences and engineering Antwerp · balance sheet 976,468 €
- Westend Healthcare Retail sale of pharmaceutical products Middelkerke · balance sheet €1.47m
- Dammed Research and experimental development on social sciences and humanities Nieuwpoort · balance sheet €1.03m
- Corcym Belgium Wholesale of pharmaceutical and medical goods Saint-Josse-ten-Noode · balance sheet €1.30m
- Alnylam Belgium Wholesale of pharmaceutical and medical goods Brussels · balance sheet €1.20m
- ExoXpert Manufacture of pharmaceutical preparations Liège · balance sheet €2.05m
- NacimCo Retail sale of medical and orthopaedic goods Jalhay · balance sheet 547,198 €
Frequently asked questions about Bioxtract
What is the revenue of Bioxtract?
Bioxtract files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Bioxtract?
In Belgium, the VAT number is the company number prefixed with BE: BE0480174942 for Bioxtract, if the company is VAT-registered. Its company number (CBE) is 0480.174.942.
Where is the registered office of Bioxtract?
According to the CBE register, the registered office of Bioxtract is in 5377 Somme-Leuze.
What is the equity of Bioxtract?
At the close of the 2025 financial year, the equity of Bioxtract amounts to 1,054,700 €, a solvency of 96.6% of total assets.
How many people work at Bioxtract?
0.5 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Bioxtract?
The register lists 4 active mandates at Bioxtract. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Bioxtract
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →